全球干细胞检测市场规模、份额、趋势和成长分析报告（2026-2034年）

预计干细胞检测市场将从 2025 年的 23.8 亿美元成长到 2034 年的 51.7 亿美元，2026 年至 2034 年的复合年增长率为 9.01%。

干细胞检测市场正迅速扩张，这主要得益于再生医学、药物研发和毒性测试领域的投资不断成长。基于干细胞的检测方法能够建构生理相关的疾病模型、疗效筛检和安全性评估模型，从而减少对动物模型的依赖。诱导多功能细胞 (iPSC) 技术、类器官和高内涵成像技术的进步进一步推动了这一增长，使研究人员能够在体外研究类人组织和复杂的细胞间相互作用。

关键驱动因素包括製药业对预测人体反应的更优转化模型的需求、监管机构鼓励采用动物试验以外的替代方法，以及干细胞分化通讯协定的学术突破。将干细胞与微流体技术、3D培养和自动化筛检相结合的平台技术提高了通量和可重复性。受託研究机构和生技公司越来越多地将干细胞检测工作外包，推动了市场服务和耗材收入的成长。

展望未来，随着标准化、检测方法检验和监管审批的推进，市场可望成熟。推动这一成长的主要动力是患者来源的诱导多能干细胞（iPS细胞）在个人化医疗中的应用，以及它们与CRISPR基因编辑技术在标靶检验方面的整合。此外，安全药理学、再生医学开发和疾病模型建构等领域的合作研究的商业机会也预计将扩大。解决检测方法的可重复性、扩充性和成本限制将是实现产业和法规环境广泛应用的关键。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球干细胞检测市场：依产品划分

• 市场分析、洞察与预测
• 装置
• 试剂和试剂盒
• 软体

第五章 全球干细胞检测市场：按类型划分

• 市场分析、洞察与预测
• 细胞活力和毒性检测
• 细胞鑑定分析
• 细胞生长化验
• 细胞分化实验
• 其他的

第六章 全球干细胞检测市场：依应用划分

• 市场分析、洞察与预测
• 再生医学和治疗方法研发
• 药物发现与开发
• 临床研究
• 其他的

第七章 全球干细胞检测市场：依最终用户划分

• 市场分析、洞察与预测
• 生物技术和製药公司
• 学术研究机构
• 其他的

第八章 全球干细胞检测市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Thermo Fisher Scientific
  • Merck KGaA
  • GE Healthcare
  • Bio-Rad Laboratories
  • Promega Corporation
  • Agilent Technologies
  • PerkinElmer
  • Lonza Group
  • Cell Biolabs
  • Stemcell Technologies
  • R&D Systems

The Stem Cell Assays Market size is expected to reach USD 5.17 Billion in 2034 from USD 2.38 Billion (2025) growing at a CAGR of 9.01% during 2026-2034.

The stem cell assays market has expanded rapidly with increased investment in regenerative medicine, drug discovery, and toxicology testing. Stem cell-based assays enable physiologically relevant models for disease modeling, efficacy screening, and safety profiling, reducing reliance on animal models. Growth has been catalyzed by advances in induced pluripotent stem cell (iPSC) technologies, organoids, and high-content imaging, which allow researchers to study human-like tissues and complex cellular interactions in vitro.

Primary drivers include pharmaceutical industry demand for better translational models to predict human responses, regulatory encouragement for alternatives to animal testing, and academic breakthroughs in stem cell differentiation protocols. Platform technologies combining stem cells with microfluidics, 3D culture, and automated screening enhance throughput and reproducibility. Contract research organizations and biotech companies increasingly outsource stem-cell assay work, boosting market services and consumables revenue.

Looking forward, the market is poised for maturation as standardization, assay validation, and regulatory acceptance improve. Expansion will be driven by personalized medicine applications-using patient-derived iPSCs-and integration with CRISPR gene-editing for target validation. Commercial opportunities in safety pharmacology, regenerative-therapeutic development, and disease-modeling collaborations will grow. Addressing assay reproducibility, scalability, and cost constraints will be key to broader adoption across industry and regulatory settings.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Instruments
• Reagents & Kits
• Software

By Type

• Cell Viability & Toxicity Assays
• Cell Identification Assays
• Cell Proliferation Assays
• Cell Differentiation Assays
• Others

By Application

• Regenerative Medicine & Therapy Development
• Drug Discovery & Development
• Clinical Research
• Others

By End-User

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific, Merck KGaA, GE Healthcare, BioRad Laboratories, Promega Corporation, Agilent Technologies, PerkinElmer, Lonza Group, Cell Biolabs, Stemcell Technologies, RD Systems
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL STEM CELL ASSAYS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Reagents & Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL STEM CELL ASSAYS MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Cell Viability & Toxicity Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cell Identification Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cell Proliferation Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Cell Differentiation Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL STEM CELL ASSAYS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Regenerative Medicine & Therapy Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinical Research Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL STEM CELL ASSAYS MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Biotechnology & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL STEM CELL ASSAYS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL STEM CELL ASSAYS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific
  • 10.2.2 Merck KGaA
  • 10.2.3 GE Healthcare
  • 10.2.4 Bio-Rad Laboratories
  • 10.2.5 Promega Corporation
  • 10.2.6 Agilent Technologies
  • 10.2.7 PerkinElmer
  • 10.2.8 Lonza Group
  • 10.2.9 Cell Biolabs
  • 10.2.10 Stemcell Technologies
  • 10.2.11 R&D Systems